Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates

Core Viewpoint - Alkermes reported quarterly earnings of $1.04 per share, exceeding the Zacks Consensus Estimate of$ 0.81 per share, and showing significant growth from $0.48 per share a year ago, indicating a strong performance in the recent quarter [1] Group 1: Earnings Performance - The earnings surprise for the recent quarter was 28.40%, compared to a previous quarter where the company reported earnings of$ 0.73 per share against an expectation of $0.78, resulting in a surprise of -6.41% [1][2] - Over the last four quarters, Alkermes has surpassed consensus EPS estimates only once [2] Group 2: Revenue Performance - Alkermes generated revenues of$ 429.99 million for the quarter ended December 2024, which surpassed the Zacks Consensus Estimate by 13.56% and increased from $377.48 million year-over-year [2] - The company has exceeded consensus revenue estimates two times in the last four quarters [2] Group 3: Stock Performance and Outlook - Alkermes shares have appreciated approximately 11.1% since the beginning of the year, outperforming the S&P 500's gain of 3.2% [3] - The future stock price movement will largely depend on management's commentary during the earnings call and the earnings outlook [3][4] Group 4: Earnings Estimates and Industry Outlook - The current consensus EPS estimate for the upcoming quarter is$ 0.39 on revenues of $325.75 million, and for the current fiscal year, it is$ 1.87 on revenues of $1.39 billion [7] - The Medical - Biomedical and Genetics industry, to which Alkermes belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable industry outlook [8]